Document is current
Any future updates will be listed below
-
Authors
Özçam, Mustafa https://orcid.org/0000-0003-1834-6942
Lin, Din L.
Gupta, Chhedi L.
Li, Allison
Gomez, J. Carlos https://orcid.org/0000-0003-0604-6838
Wheatley, Lisa M.
Baloh, Carolyn H.
Sanda, Srinath
Jones, Stacie M.
Lynch, Susan V. https://orcid.org/0000-0001-5695-7336
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI128482, AI148104, UM1AI160040, AI089473)
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 10 June 2025
First Online: 9 July 2025
Competing interests
: S.V.L. is a board member and consultant for the biotechnology company Siolta Therapeutics, Inc., and holds stock in the company. She also consults for Sanofi and for the Atria Institute of New York. S.S. has served on a scientific advisory board for Sanofi. S.M.J, reports grant support from the NIH-NIAID and Food Allergy Research & Education (FARE), clinical trials support Genentech, ALK-Abello, Inc., Aravax Pty, Ltd., DBV Technologies, Inc., Genentech, Inc., Novartis, Inc., Regeneron Pharmaceuticals, Inc., and personal fees from LAmAb Bio, Inc. M.Ö., D.L.L., C.L.D., A.L., J.C.G., L.M.W., and C.H.B. declare that they have no relevant competing interests.
